How to Get Vyleesi in Utah

What Bremelanotide Is and Why It Exists

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist that the FDA approved in June 2019 specifically for acquired, generalized HSDD in premenopausal women 1. Unlike flibanserin, which requires daily oral dosing, bremelanotide is injected subcutaneously on an as-needed basis roughly 45 minutes before anticipated sexual activity 2. That on-demand dosing model gives patients more control over when they experience the drug's effects.

The mechanism is distinct from any other approved sexual-health medication. Bremelanotide activates MC4R pathways in the central nervous system, modulating excitatory signaling that contributes to sexual desire. It does not act on serotonin, dopamine reuptake, or hormonal axes. The FDA based its approval primarily on the two RECONNECT phase 3 trials, which enrolled 1,247 premenopausal women with HSDD and measured changes in desire using the Female Sexual Function Index (FSFI-desire domain) and distress using the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) 3.

In RECONNECT, bremelanotide 1.75 mg produced a statistically significant 0.5-point improvement in the FSFI-desire domain score versus placebo (P<0.001), and a 0.7-point greater reduction in FSDS-DAO Item 13 distress score compared with placebo over 24 weeks 3. Dr. Sheryl Kingsberg, a lead RECONNECT investigator, stated: "Bremelanotide represents a fundamentally different pharmacologic approach to HSDD, one that works through the melanocortin system rather than requiring daily serotonergic modulation" 3.

Utah Telehealth Prescribing Rules for Vyleesi

Utah allows licensed prescribers to issue Vyleesi prescriptions through telehealth. The Utah Telehealth Act (Utah Code 26-60) permits the establishment of a provider-patient relationship via synchronous audio-video consultation without requiring a prior in-person visit 4. This is a real advantage for women in rural parts of the state, where sexual medicine specialists are scarce.

A prescriber must hold an active Utah license or a license recognized through an interstate compact. For controlled substances, Utah has specific telehealth restrictions, but bremelanotide is not a scheduled drug, so those restrictions do not apply. The prescriber conducts a standard clinical interview, reviews screening questionnaires (typically the FSFI and FSDS-DAO), confirms the HSDD diagnosis, and writes the prescription electronically.

Most telehealth platforms specializing in women's sexual health can see Utah patients. Expect the initial consultation to last 20 to 30 minutes. Follow-up visits are shorter, often 10 to 15 minutes, and focus on tolerability, nausea management, and efficacy assessment.

Who Can Prescribe Vyleesi in Utah

Three categories of prescribers can write a bremelanotide prescription in Utah. MDs and DOs with active Utah medical licenses have full prescriptive authority. Nurse practitioners (NPs) in Utah can prescribe independently if they hold a controlled substance license, though bremelanotide does not require one. NPs who have completed fewer than 10,000 practice hours must maintain a collaborative agreement with a physician 5. Physician assistants (PAs) prescribe under a supervisory agreement.

Any of these provider types can diagnose HSDD and prescribe bremelanotide, provided they perform the clinical evaluation required by the drug's labeling. The ISSWSH (International Society for the Study of Women's Sexual Health) process of care algorithm recommends screening with validated instruments and ruling out medication-induced causes, relationship factors, and other psychiatric conditions before diagnosing HSDD 6. You do not need a specialist. A well-informed primary care provider or gynecologist can manage the entire prescribing workflow.

Labs and Clinical Screening Before Your First Dose

The FDA label for bremelanotide does not mandate specific laboratory tests before prescribing 2. Most clinicians order a basic panel anyway to rule out medical contributors to low desire. A reasonable pre-prescribing workup includes:

Hormonal panel. Serum testosterone (total and free), estradiol, DHEA-S, and thyroid-stimulating hormone (TSH). Low testosterone or thyroid dysfunction can independently suppress sexual desire and should be treated before attributing symptoms solely to HSDD 7.

Metabolic screen. Fasting glucose or HbA1c if diabetes risk factors are present. Hemoglobin and hematocrit to rule out anemia.

Medication review. SSRIs, SNRIs, combined oral contraceptives, and spironolactone are common desire-suppressing medications. The 2019 Endocrine Society guideline on female sexual dysfunction notes that medication-related causes should be identified and addressed before initiating pharmacotherapy for HSDD 7.

Blood pressure. Bremelanotide can transiently raise blood pressure by 2 to 3 mmHg following injection. The FDA label contraindicates the drug in patients with uncontrolled hypertension or known cardiovascular disease 2. A single office or telehealth blood pressure reading is sufficient for clearance.

A prescriber following these steps can complete the evaluation in one visit. No imaging or invasive testing is needed.

Insurance, Prior Authorization, and Cost in Utah

This is where the process gets complicated. Utah Medicaid does not cover Vyleesi for HSDD. Most commercial plans place bremelanotide on a specialty tier, and many require prior authorization before dispensing.

Prior authorization documentation typically includes: a completed prior authorization form from the insurer, chart notes confirming an HSDD diagnosis using DSM-5 criteria, documentation that the patient has tried non-pharmacologic interventions (such as psychotherapy or sex therapy), and a statement that the patient is premenopausal. Some insurers also require documentation that flibanserin was tried and either failed or was not tolerated.

Without insurance, brand-name Vyleesi costs approximately $900 to $1,000 for a four-autoinjector carton (each autoinjector delivers one 1.75 mg dose). Palatin Technologies has offered copay assistance programs that can reduce out-of-pocket costs for commercially insured patients. The AMAG/Palatin patient savings card, when active, has historically brought the per-dose copay to $0 for eligible patients, though program availability and terms change. Compounded bremelanotide from a 503A pharmacy can cost significantly less, often $100 to $300 per month depending on the number of doses dispensed.

503A Compounding Pharmacies in Utah

Utah licenses 503A compounding pharmacies under the Utah Division of Occupational and Professional Licensing (DOPL). These pharmacies can compound bremelanotide from bulk drug substance when a patient-specific prescription exists 8. The distinction matters. A 503A pharmacy fills individual prescriptions, while 503B outsourcing facilities produce compounded drugs in larger batches without patient-specific prescriptions.

For bremelanotide, 503A compounding typically involves preparing pre-filled syringes or multi-dose vials at the 1.75 mg dose. The patient receives a prescription from their clinician, the pharmacy compounds the medication, and it ships directly to the patient's address in Utah via overnight or two-day cold-chain shipping. Bacteriostatic water and insulin-type syringes are included.

Before choosing a compounding pharmacy, verify three things. First, confirm the pharmacy holds a current Utah DOPL license. Second, ask whether the pharmacy sources bremelanotide from an FDA-registered bulk supplier. Third, confirm they follow USP 797 and USP 800 sterile compounding standards 9. Your prescribing clinician can often recommend a vetted compounding pharmacy they already work with.

How to Self-Administer the Injection

Vyleesi is a subcutaneous injection, similar in technique to insulin. The brand-name product comes in a prefilled autoinjector. Compounded versions are usually supplied in vials with insulin syringes.

The injection goes into the abdomen at least two inches from the navel. Rotate injection sites to prevent lipodystrophy. Clean the site with an alcohol swab, pinch the skin, insert the needle at a 45-to-90-degree angle, and inject. The whole process takes under 30 seconds. Most patients report the injection itself as painless or mildly uncomfortable.

Timing is specific: inject approximately 45 minutes before anticipated sexual activity 2. Do not inject more than once in 24 hours, and do not exceed 8 doses in a calendar month. The FDA labeling sets these limits based on the safety data from RECONNECT and the open-label extension studies.

Dr. Anita Clayton, a professor of psychiatry and neurobehavioral sciences at the University of Virginia who contributed to the bremelanotide clinical program, has noted: "The on-demand model allows women to use the medication only when they choose to, which many patients prefer over a daily pill" 3.

Managing Nausea and Other Side Effects

Nausea is the most common adverse event. In the RECONNECT trials, 40% of bremelanotide-treated patients reported nausea compared with 1.3% on placebo 3. Most episodes were mild to moderate and decreased with repeated dosing. By month three of the open-label extension, the proportion of patients reporting nausea per dose dropped substantially.

Practical nausea mitigation strategies include taking the injection after a light meal rather than on an empty stomach, pre-treating with ondansetron 4 mg orally 30 minutes before the bremelanotide injection, and staying hydrated. Some clinicians suggest starting with a lower compounded dose (e.g., 1.0 mg) for the first two to three uses to build tolerance, though this is off-label.

Other reported side effects from the clinical trials include flushing (20.3%), headache (11.3%), and injection site reactions (5.4%) 2. Hyperpigmentation of the gums, face, and breasts occurred in some patients during longer-term use, related to the melanocortin mechanism of action. This effect was generally reversible after discontinuation. The FDA recommends against use in patients with a history of melanoma or at high risk for melanoma given the melanocortin pathway involvement.

Timeline: Consultation to First Dose in Utah

Here is a realistic timeline for a Utah patient starting from scratch.

Week 1. Schedule a telehealth or in-person consultation. Many telehealth platforms offer appointments within 2 to 5 business days. Your provider takes a history, administers screening questionnaires, and orders labs if needed.

Week 1 to 2. Complete labs at a local draw site (Quest, Labcorp, or a hospital lab). Results return in 1 to 3 business days.

Week 2. Follow-up visit (often 10 minutes by telehealth) to review labs and finalize the prescription. The clinician sends the Rx electronically to your chosen pharmacy.

Week 2 to 3. If using a compounding pharmacy, expect 3 to 7 business days for compounding and shipping. If using brand-name Vyleesi, the specialty pharmacy processes prior authorization (which can take 5 to 14 business days depending on the insurer) before dispensing.

Week 3 to 4. Medication arrives. You self-administer the first dose.

Total elapsed time ranges from 10 days (compounded, no PA needed) to 4 weeks (brand-name with prior authorization). Women in the Salt Lake City, Provo, and Ogden metro areas can usually complete the lab draw within a day or two. Those in more rural areas of Utah may need to factor in additional travel time for the blood draw.

Who Should Not Use Bremelanotide

The FDA label lists specific contraindications 2. Bremelanotide should not be used by patients with uncontrolled hypertension or cardiovascular disease due to its transient pressor effect. It is contraindicated in postmenopausal women and in men (it is not approved for either group). Women currently using naltrexone must not use bremelanotide, as concurrent administration significantly decreases the naltrexone blood concentration, potentially reducing its efficacy for alcohol or opioid use disorder treatment 10.

Bremelanotide has not been studied in pregnant or breastfeeding women. The prescribing information recommends pregnancy testing if clinically indicated before initiating treatment. Women using bremelanotide should use effective contraception if pregnancy is not desired 2.

Patients with hepatic impairment (Child-Pugh class B or C) or severe renal impairment (eGFR <30 mL/min) should avoid bremelanotide, as pharmacokinetic data in these populations are limited.